DrugTimes

Novo and Eli Lilly’s favored #ADC #payload, are you interested? | DrugTimes BD Project On July 8, 2024, the UK #biotechnology company #MyricxBio announced the completion of its Series A financing, raising $114 million. This round of financing was co-led by #NovoHoldings and #Abingworth, and included other new investors such as #BritishPatientCapital, #CancerResearchHorizons, and #EliLilly and Company, as well as founding investors #BrandonCapital and #SofinnovaPartners. Novo Holdings is the investment arm of the #NovoNordiskFoundation, and Eli Lilly and Company is a globally renowned #pharmaceuticalcompany. Myricx Bio focuses on developing a novel N-Myristoyltransferase inhibitor (#NMTi) as a payload for #antibodydrugconjugates (#ADC). NMTi is a new type of ADC payload capable of specifically lipid-modifying key protein targets essential for the survival of #cancer cells, thereby inhibiting the growth of cancer cells. Myricx has demonstrated that its NMTi-ADC has achieved complete and durable tumor regression in various solid cancer models and has shown strong bystander activity. The team of Myricx was founded by Professor Ed Tate, Dr. Roberto Solari, and Dr. Andrew Bell, and has been joined by several professionals with rich experience in the field of ADCs, such as Dr. Robin Carr and Dr. Francesca Zammarchi. The company’s R&D pipeline includes four products, among which MYX2449 is an #HER2 targeting ADC that has shown high efficacy and tolerability in #preclinical studies. The financing and R&D progress of Myricx demonstrate the attention and investment of large pharmaceutical companies such as Novo Nordisk and Eli Lilly in the new type of ADC payload technology, which may herald a new direction in the field of tumor treatment in the future. DrugTimes Pipeline (Loongline) has a promising NMTi product in need of cooperation, with flexible cooperation forms. If your company is interested in the new NMTi payload, please contact DrugTimes BD team as soon as possible! Please indicate the project code: BP-20240531-OR-76 We will discuss in detail with you. Thank you! Contact person: Richard Phone: 17821449819 WeChat: DrugTimes_BD Email: BD@drugtimes.cn For more #BDopportunities, please visit https://lnkd.in/giPU3hxm #drugdiscovery #drugdevelopment #businessdevelopment #antibody #antitumor #codevelopment #DrugTimes

#NASDAQ listed companies are looking for #obesity drugs with the potential for #weightloss and #musclegain. The current stage can be as early as #hit and #lead. If your company is interested in this opportunity, please contact the #DrugTimes BD team as soon as possible! For more #licensing opportunities, please follow DrugTimes. Thank you very much!~ https://lnkd.in/g-awFNHh

👍 Totally agree! "#Innovation is the foundation for any Biotech company, while #commercialization is another factor to measure the success."

📢 【Licensing Out Opportunities】 U.S. public biotech companies are looking for products that meet the following criteria (innovative ADCs, innovative bispecific antibodies). If your company has suitable products and is interested in this opportunity, we are happy to recommend. (1) Focus on innovative drugs, modified new drugs (505B2) are not considered, even if individual products claim to have obvious advantages and differentiation; (2) Focus on ADCs, bispecific/multispecific antibodies, monoclonal antibodies, and payloads are not considered; (3) Focus on targets with less competition, such as HER2, EGFR, CLDN18.2, TROP2, and other highly competitive targets are not considered, even if individual products claim to have obvious advantages and differentiation; (4) Indications are not limited, focusing on oncology, including hematologic malignancies and solid tumors (including lung cancer, breast cancer, and other highly competitive major cancer types). Autoimmune, CNS, digestive system, and other disease areas/indications are not considered; (5) In terms of stage: Products from the ongoing IND-enabling phase to the completion of Phase 1 clinical trials are considered, and products with only Chinese clinical data are also acceptable. Products outside the aforementioned stages are not considered. Please contact DrugTimes BD Team at BD@drugtimes.cn. Many thanks! 🌹

American listed companies are looking for innovative ADCs and bispecific antibodies. Are you interested in this opportunity? | DrugTimes BD Project American listed companies are sincerely seeking innovative ADCs and bispecific antibodies. The specific requirements are as follows: Stage: IND, Phase 1 clinical trial Molecular entities: ADCs, bispecific antibodies Targets: Innovative targets (not competitive, not crowded) Rights Interested: Global rights, ex-China rights Preferred cooperation model: Licensing If your company is interested in this opportunity, please contact the DrugTimes BD team as soon as possible! Please indicate the project code: BP-20240725-EE-77 We will discuss in detail with you. Thank you! Contact person: Richard Phone: 17821449819 WeChat: DrugTimes_BD Email: BD@drugtimes.cn

📢 Today is 2024-07-10, over the past one month or so, we have posted BD related posts on LinkedIn, including #ProductforLicensing, #RequestforProduct. 📒 Herein, we would like to compile all the posts on Request for Product to date. ❤️ Hopefully more and more friends will take advantge of these Business Development (#BD) opportunities. 1️⃣ 【Product Wanted】HER2 Small Molecules That Can Penetrate BBB https://lnkd.in/g_GkQTwR 2️⃣ 【Urgent Request】European and American biotech companies are interested in licensing drugs for PD, AD and other CNS diseases https://lnkd.in/g7vvEp5U 3️⃣ 【Urgent】MNC, China big pharma, US biotech are looking for ActRIIA and ActRIIB Inhibitors for obesity and other indications https://lnkd.in/gsYk_tdt 4️⃣ TOP10 MNC Seeking FIC or BIC Products: IPF https://lnkd.in/gUuyGxPR 5️⃣ TOP10 MNC Seeking FIC or BIC Products: COPD https://lnkd.in/gBqzb_Je 6️⃣ TOP10 MNC Seeking FIC or BIC Products: Asthma https://lnkd.in/gsGSSBWt 7️⃣ TOP10 MNC Seeking FIC or BIC Products: Inflammatory bowel disease (IBD) https://lnkd.in/gtx5BwaB 8️⃣ Are you looking for a promising product to license in? We can help you, and completely free of charge! https://lnkd.in/gAAYFaFx 🚀 More opportunities will be posted here on hashtag #DrugTimes. Please stay tuned. FYI. Currently >210000 professionals working on #drugdiscovery, #drugdevelopment, #businessdevelopment, #investment, from #MNC, #Pharma, #biotech, #CRO, #CDMO, #university, #biotechhub, etc. are in our network. We sincerely appreciate their trust and support 🌹

📢 Today is 2024-07-09, over the past one month or so, we have posted BD related posts on LinkedIn, including #ProductforLicensing, #RequestforProduct. 📒 Herein, we would like to compile all the posts on Product for Licensing to date. ❤️ Hopefully more and more friends will take advantge of these Business Development (#BD) opportunities. 🥇 【Product for Licensing】A PD-L1 siRNA that Can Boost Immune Response for CHB Functional Cure https://lnkd.in/gJ2Hqdis 🥈 【Product for Sale】Innovative Biological Product for Systemic Lupus Erythematosus (SLE) https://lnkd.in/g2xRE-Gg 🥉 【Product for Licensing】Better Clinical Compound for Pulmonary IPF & PPF & ILD https://lnkd.in/gc82ZbVs 4️⃣ 【Product for Licensing】ANTI-CDCP1 mAb and ADC https://lnkd.in/ghzfdXQ5 5️⃣ 【Product for Licensing】CLDN6 X 4-1BB bispecific antibody https://lnkd.in/gTk8cEby 6️⃣ A Novel Long-acting GDF15 Analog for the Treatment of Obesity https://lnkd.in/gxPm4-xK 7️⃣ DPP4i+SGLT2i Combination Therapy for CAVD with first-in-class potential https://lnkd.in/gyXyxG5C 8️⃣ A long-acting anti-TL1A mAb with best-in-class potential https://lnkd.in/gg9KvDf5 9️⃣ Products for Licensing (as of 2024-04-28) https://lnkd.in/g-_T4nfq 🔟 Do you have a promising product to license out? We can help you! https://lnkd.in/gdFYQ68V More opportunities will be posted here on #DrugTimes. Please stay tuned. FYI. Currently >210000 professionals working on #drugdiscovery, #drugdevelopment, #businessdevelopment, #investment, from #MNC, #Pharma, #biotech, #CRO, #CDMO, #university, #biotechhub, etc. are in our network. We sincerely appreciate their trust and support 🌹

Dear Friends, Today marks the 3rd of July, 2024, and it is with immense pleasure that we announce the launch of our DrugTimes LinkedIn page, now officially open for engagement. We are thrilled at the prospect of collaborating with you to achieve not just a win-win scenario, but a multifaceted win that extends beyond our immediate partnerships. Our collective efforts will ultimately contribute to the development of innovative drugs that will improve the lives of patients. We look forward to a journey of shared success and positive impact in the pharmaceutical and biotechnology sectors. Here's to a future of breakthroughs and better health for all! 【About DrugTimes】 DrugTimes is a leading consulting service platform rooted in new media, boasting a network of over 210,000 R&D and investment professionals. Our platform garners an impressive 22 million times of annual engagement through reading and viewing. Over the years, we have earned a stellar reputation within China's pharmaceutical and biotechnology sectors. Our service offerings are diverse and include: 1. Branding Services: We specialize in elevating your company's brand, products, and services to our extensive network of professionals. 2. Event Planning and Execution: With a track record of organizing over 250 successful onsite and online events, we bring expertise to every occasion. 3. Business Development (BD) Services: Over the past five years, our contributions have led to the successful completion of nearly one deal per year, with the most significant deal featuring a $35 million upfront payment and a total value exceeding $200 million. Today, we are approached by numerous pharmaceutical and biotechnology companies, including multinational corporations, seeking collaboration. Leveraging our extensive resources and rich experience, we are confident in our ability to connect you with high-quality partners for your promising products in an efficient and effective manner.